Advertisement
YOU ARE HERE: LAT HomeCollectionsImclone Systems Company
IN THE NEWS

Imclone Systems Company

BUSINESS
October 21, 2003 | From Bloomberg News
Martha Stewart won a ruling barring prosecutors from using an e-mail she wrote to her lawyer explaining her trading as evidence at her trial. In a June 23, 2002, e-mail, Stewart, the former chief executive of Martha Stewart Living Omnimedia Inc., offered an account to her attorney of why she sold shares in ImClone Systems Inc. The e-mail was meant to assist her lawyer's investigation of the case, Stewart said. The next day, Stewart sent the same e-mail to her daughter Alexis.
Advertisement
BUSINESS
September 9, 2003 | From Associated Press
A federal judge said Monday that she saw no indication of a breach of grand jury secrecy in the Martha Stewart case, rejecting defense demands that the government investigate the source of pre-indictment leaks. U.S. District Judge Miriam Goldman Cedarbaum said she found it difficult to understand how lawyers for Stewart believed their client might have been prejudiced if someone had leaked the fact that the indictment would not include a charge of insider trading.
BUSINESS
July 31, 2002 | Reuters
Prosecutors are threatening former ImClone Systems Inc. Chief Executive Samuel D. Waksal with an unusually lengthy jail sentence amid a broad move by the government to crack down on corporate wrongdoing. Federal prosecutors are demanding that Waksal agree to seven to 10 years in prison as part of a plea bargain, according to a person familiar with the situation.
BUSINESS
March 4, 2004 | Thomas S. Mulligan, Times Staff Writer
After 27 witnesses and 19 days of testimony and arguments, the jury is officially out on Martha Stewart. The panel -- as diverse as New York -- includes a Uganda-born pharmacist, a clergywoman, an Italian-language interpreter and a man whose regular poker game includes Wall Street pros: stockbrokers and "hedge fund people." The eight women and four men began deliberations Wednesday after U.S.
BUSINESS
March 9, 2004 | From Times Staff and Wire Services
Martha Stewart met on Monday with federal probation officials who will recommend a sentence for her conviction on charges of lying about a stock sale, then emerged from the courthouse to thank her supporters. Stock in Stewart's namesake empire slid an additional 8%, and the board of Martha Stewart Living Omnimedia met to discuss life without her. The probation meeting is the first step toward sentencing.
BUSINESS
March 5, 2004 | From Associated Press
The Martha Stewart jury indicated Thursday that it was focusing on whether her stockbroker committed perjury in an interview about a phone message he left for the lifestyles entrepreneur. Jurors completed their second day of deliberations without reaching a verdict against Stewart or broker Peter E. Bacanovic. They were to resume deliberating this morning.
BUSINESS
July 4, 2003 | From Associated Press
ImClone Systems Inc., whose problems with the Food and Drug Administration led to a stock scandal, on Thursday posted a wider first-quarter loss on rising expenses. The New York-based cancer drug developer said its net loss was $34.8 million, or 47 cents a share, compared with a loss of $30.1 million, or 41 cents a share, a year earlier. Revenue rose 5.5% to $19.6 million from $18.6 million. Operating expenses in the quarter were $53.9 million, compared with $48.2 million last year.
BUSINESS
January 27, 2003 | From Associated Press
Martha Stewart estimates that the federal investigation into her ImClone Systems stock trade has cost her about $400 million, according to an interview with the New Yorker magazine, which reaches newsstands today. Stewart told New Yorker writer Jeffrey Toobin that the losses have been mostly in the decline of her more than 30 million shares in her multimedia company, but also in legal fees and lost business opportunities.
BUSINESS
April 28, 2004 | From Dow Jones/Associated Press
Biotechnology company ImClone Systems Inc.'s first-quarter earnings blew past consensus expectations because of the strength of its colon-cancer drug Erbitux, which recently hit the market. ImClone posted a profit of $62.7 million, or 76 cents a share, contrasted with a loss of $34.8 million, or 47 cents, a year earlier. Analysts on average had expected 17 cents a share, according to a survey by Thomson First Call. ImClone reported revenue of $109.
BUSINESS
June 10, 2003 | From Associated Press
Martha Stewart thanked her admirers Monday for 40,000 e-mails of praise and support that she said have flooded a Web site she set up to defend her name against a federal indictment. Image consultants say it's part of a shrewd campaign to win the battle for public opinion -- and influence potential jurors. "This is brilliant," said Seth Siegel, co-founder of the Beanstalk Group, a trademark licensing agency. "She is shoring up her base and simultaneously getting ready for a trial."
Los Angeles Times Articles
|